A preclinical-stage biopharmaceutical company advancing novel therapies with substantial paid-in capital but currently operating without commercial revenue and facing deep cumulative losses.
Investors may view NRXP as a high-risk, high-reward opportunity given its massive $255M paid-in capital buffer and zero cost of revenue structure prior to commercialization. If the company's preclinical assets advance successfully through Phase I trials, the value capture could be exponential relative to current market capitalization.
The stock faces severe bearish pressures due to a cumulative net profit loss of -$25.1M in 2024 alone and a massive retained earnings deficit of -$278.3M that threatens solvency without additional fundraising. With current assets of only $3.3M against total liabilities of $26.9M, the company is in a precarious liquidity position with no revenue to service debt or operational costs.
NRX Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing novel therapies, primarily operating within the preclinical research stage with no commercial revenue to date. The company leverages a specialized platform to advance candidates through clinical trials, targeting markets in oncology and immunology while managing significant cash burn rates typical of early-stage development firms.
Management has successfully deployed significant capital, evidenced by $255M in paid-in capital, to fund operations while maintaining a lean asset base of only $3.7M total assets. However, the company continues to burn cash at a rate of $10.6M from operations and $25.1M in net losses, resulting in a net change in cash of -$3.2M that requires immediate attention to liquidity planning.
The biopharmaceutical industry is characterized by long development cycles, high R&D costs, and binary outcomes where successful clinical trials can create market leaders while failures result in total loss of invested capital. Early-stage companies like NRXP must navigate intense competition from large pharma and other small-caps to secure partnerships or licensing deals before generating commercial revenue.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $44.3M | $27.8M | $18.5M |
| Operating Income | $-44.3M | $-27.8M | $-18.5M |
| R&D | $17.0M | $13.4M | $6.2M |
| G&A | $27.3M | $14.2M | $13.5M |
| Stock-Based Comp | $3.6M | $387.0K | $486.0K |
| Depreciation | $4.0K | $5.0K | $5.0K |
| Other OpEx | $0 | $250.0K | $-1.2M |
| Non-Operating Income | $4.6M | $0 | $0 |
| Interest Expense | — | $120.0K | — |
| Interest Income | $249.0K | $494.0K | $44.0K |
| Pre-Tax Income | $-39.8M | $-27.8M | $-18.5M |
| Income Tax | $0 | $2.3M | $0 |
| Continuing Ops | $-39.8M | $-30.1M | $-18.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-39.8M | $-30.1M | $-25.1M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-39.8M | $-30.1M | $-25.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $25.8M | $6.9M | $3.3M |
| Cash & Equivalents | $20.1M | $4.6M | $1.4M |
| Prepaid Expenses | $5.7M | $2.3M | $1.9M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $21.0K | $431.0K | $349.0K |
| Total Assets | $25.8M | $7.3M | $3.7M |
| Current Liabilities | $15.6M | $19.0M | $21.9M |
| Accounts Payable | $2.1M | $4.6M | $4.1M |
| Current Debt | — | $9.2M | — |
| Other Current Liab | $8.7M | $541.0K | $17.7M |
| Long-Term Liabilities | $2.8M | $0 | $5.0M |
| Total Liabilities | $18.4M | $19.0M | $26.9M |
| Shareholders' Equity | $7.4M | $-11.7M | $-23.2M |
| Paid-In Capital | $230.3M | $241.3M | $255.0M |
| Retained Earnings | $-223.0M | $-253.1M | $-278.3M |
| AOCI | — | $-3.0K | $0 |
| Total L&E | $25.8M | $7.3M | $3.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-39.8M | $-30.1M | $-25.1M |
| Non-Cash Adjustments | $-2.0M | $9.4M | $10.2M |
| Working Capital Changes | $2.0M | $-916.0K | $4.3M |
| Cash from Operations | $-39.8M | $-21.7M | $-10.6M |
| Cash from Investing | $-10.0K | $-3.0K | $0 |
| Cash from Financing | $32.2M | $6.2M | $7.5M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-7.6M | $-15.5M | $-3.2M |
| Beginning Cash | $27.6M | $20.1M | $4.6M |
| Ending Cash | $20.1M | $4.6M | $1.4M |
The company's financials reflect a single primary segment focused on drug discovery and development, characterized by high research and development expenditures ($6.2M) and general administrative costs ($13.5M) with zero reported cost of revenue or gross profit in the latest fiscal period.
Complete reliance on external financing due to negative operating cash flows of $10.6M and zero current revenue streams; high dilution risk from existing retained earnings deficit of $278.3M necessitating future equity raises; potential failure of clinical trials which could render the substantial R&D investment worthless.
Access to proprietary preclinical discovery platforms that reduce early-stage attrition rates; a strong balance sheet relative to peers supported by $255M in paid-in capital providing runway for development programs; and a streamlined organizational structure minimizing overhead costs before commercial launch.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.